vs
Side-by-side financial comparison of MOGU Inc. (MOGU) and Neuphoria Therapeutics Inc. (NEUP). Click either name above to swap in a different company.
MOGU Inc. is the larger business by last-quarter revenue ($19.5M vs $15.0M, roughly 1.3× Neuphoria Therapeutics Inc.). Neuphoria Therapeutics Inc. runs the higher net margin — 75.1% vs -44.3%, a 119.4% gap on every dollar of revenue.
Mogu Mogu is a brand of fruit-flavoured drink with pieces of nata de coco, produced by Thailand-based Sappe Public Company Limited and exported to many international markets, especially South Korea, the Philippines, Indonesia and France.
Neuphoria Therapeutics Inc is a clinical-stage biopharmaceutical company focused on researching and developing innovative targeted therapies for unmet medical needs in neurological and psychiatric conditions, including anxiety, treatment-resistant depression, and other central nervous system disorders. Its core R&D efforts prioritize delivering safer, more effective treatment options for patient groups with limited existing care alternatives.
MOGU vs NEUP — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.5M | $15.0M |
| Net Profit | $-8.6M | $11.3M |
| Gross Margin | 0.0% | — |
| Operating Margin | -71.6% | 79.8% |
| Net Margin | -44.3% | 75.1% |
| Revenue YoY | -12.4% | — |
| Net Profit YoY | -5.0% | — |
| EPS (diluted) | $0.00 | $6.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 25 | $19.5M | $15.0M | ||
| Q1 24 | $22.2M | — |
| Q1 25 | $-8.6M | $11.3M | ||
| Q1 24 | $-8.2M | — |
| Q1 25 | 0.0% | — | ||
| Q1 24 | 0.0% | — |
| Q1 25 | -71.6% | 79.8% | ||
| Q1 24 | -49.4% | — |
| Q1 25 | -44.3% | 75.1% | ||
| Q1 24 | -37.0% | — |
| Q1 25 | $0.00 | $6.55 | ||
| Q1 24 | $0.00 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.3M | $17.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $70.1M | $26.0M |
| Total Assets | $118.3M | $30.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | $52.3M | $17.0M | ||
| Q1 24 | $58.2M | — |
| Q1 25 | $70.1M | $26.0M | ||
| Q1 24 | $81.5M | — |
| Q1 25 | $118.3M | $30.7M | ||
| Q1 24 | $130.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-9.4M | $11.5M |
| Free Cash FlowOCF − Capex | $-10.7M | — |
| FCF MarginFCF / Revenue | -55.2% | — |
| Capex IntensityCapex / Revenue | 7.1% | — |
| Cash ConversionOCF / Net Profit | — | 1.02× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | $-9.4M | $11.5M | ||
| Q1 24 | $-5.6M | — |
| Q1 25 | $-10.7M | — | ||
| Q1 24 | $-18.6M | — |
| Q1 25 | -55.2% | — | ||
| Q1 24 | -84.0% | — |
| Q1 25 | 7.1% | — | ||
| Q1 24 | 58.7% | — |
| Q1 25 | — | 1.02× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
